India Grants First Compulsory License To Natco For Bayer’s Nexavar; Disappointed, Bayer May Challenge Decision
This article was originally published in The Pink Sheet Daily
India grants compulsory license to Natco for Bayer’s Nexavar; ruling could start run on more CLs.
You may also be interested in...
At a House hearing PhRMA representative cites the need for 12 years test data exclusivity for biologics in the Trans-Pacific Partnership Agreement. Separately, USTR issues its 2012 Special 301 Report.